These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 31343326)
21. From hypertrophic cardiomyopathy to transthyretin amyloidosis: an unusual case and challenging diagnosis. Petkow-Dimitrow P; Rajtar-Salwa R; Holcman K; Kostkiewicz M; Rubiś P Pol Arch Intern Med; 2020 Feb; 130(2):153-154. PubMed ID: 31933485 [No Abstract] [Full Text] [Related]
23. Vitreous opacities in a case of familial amyloidotic polyneuropathy associated with a transthyretin Lys 54. Imasawa M; Toda Y; Sakurada Y; Imai M; Iijima H Acta Ophthalmol Scand; 2004 Oct; 82(5):635-7. PubMed ID: 15453875 [No Abstract] [Full Text] [Related]
24. Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management. Alcantara M; Mezei MM; Baker SK; Breiner A; Dhawan P; Fiander A; Fine NM; Hahn C; Katzberg HD; Khayambashi S; Massie R; Matte G; Putko B; Siddiqi Z; Delgado D; Bril V Can J Neurol Sci; 2022 Jan; 49(1):7-18. PubMed ID: 33631091 [TBL] [Abstract][Full Text] [Related]
25. Myopathic phenotype of familial amyloid polyneuropathy with a rare transthyretin variant: ATTR Ala45Asp. Misumi Y; Doki T; Ueda M; Obayashi K; Tasaki M; Tamura A; Ando Y Amyloid; 2014 Sep; 21(3):216-7. PubMed ID: 24953234 [No Abstract] [Full Text] [Related]
26. Characterization of untyped cardiac amyloidosis by mass spectrometry in a patient with Gly6Ser transthyretin polymorphism in fatal cardiogenic shock. Damy T; Plante-Bordeneuve V; Dogan A Arch Cardiovasc Dis; 2014 Dec; 107(12):706-8. PubMed ID: 24070596 [No Abstract] [Full Text] [Related]
27. Hereditary transthyretin amyloidosis associated with a transthyretin variant Thr59Arg. Watanabe T; Obayashi K; Misumi Y; Tasaki M; Shinriki S; Ando T; Akagami T; Ueda M; Yamashita T; Hirotani S; Ando Y Amyloid; 2017 Mar; 24(sup1):119. PubMed ID: 28434332 [No Abstract] [Full Text] [Related]
36. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641 [No Abstract] [Full Text] [Related]
37. A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G > T, p.Ala140Ser). Patel K; Tagoe C; Bieri P; Weidenheim K; Tauras JM Amyloid; 2018 Sep; 25(3):211-212. PubMed ID: 30039724 [No Abstract] [Full Text] [Related]
38. Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis. Mahfouz M; Maruyama R; Yokota T Methods Mol Biol; 2020; 2176():87-98. PubMed ID: 32865784 [TBL] [Abstract][Full Text] [Related]
39. Vitreal deposits in Val71Ala transthyretin amyloidosis. Suan D; Booth DR; Kennedy IH; Downie J; Earls P; Gottlieb D; Stewart GJ; Lin MW Intern Med J; 2012 Jan; 42(1):106-8. PubMed ID: 22276564 [No Abstract] [Full Text] [Related]
40. Misdiagnosis in late versus early onset hATTR amyloidosis patients: experience from a reference centre. Falcão de Campos C; Parreira S; Conceição I Amyloid; 2019; 26(sup1):37-38. PubMed ID: 31343293 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]